Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer

Author(s): Einat Slonimsky, Mark Tulchinsky*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 31 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

This review of radioactive iodide treatment (RAIT) extends from historical origins to its modern utilization in differentiated thyroid cancer (DTC). The principles embedded in the radiotheragnostics (RTGs) paradigm are detailed.

The diverse approaches in current practice are addressed, and this broad variability represents a major weakness that erodes our specialty’s trust-based relationship with patients and referring physicians. The currently developing inter-specialty collaboration should be hailed as a positive change. It promises to clarify the target-based terminology for RAIT. It defines RAIT of post total thyroidectomy (PTT), presumably benign thyroid as ‘remnant ablation’ (RA). ‘Adjuvant treatment’ (AT) referrers to RAIT of suspected microscopic DTC that is inherently occult on diagnostic imaging. RAIT directed at DTC lesion(s) overtly seen on diagnostic imaging is termed ‘treatment of known disease’ (TKD).

It was recently recognized that a ‘recurrent’ DTC is actually occult residual DTC in the majority of cases. Thyroglobulin with remnant uptake concord (TRUC) method (aka Tulchinsky method) was developed to validate that a benign remnant in the post-thyroidectomy neck bed, as quantified by the RAI uptake, is concordant with a measured thyroglobulin (Tg) level at the time of the initial post-thyroidectomy evaluation. It allows recognition of occult residual DTC contribution to post-thyroidectomy Tg. Case examples demonstrate the application of the TRUC method for a logical selection of a specific RAIT category, using imaging-guided identification and management of RAI-avid versus RAI-nonavid residual DTC, i.e. the radiotheragnostics paradigm.

Keywords: Radioactive Iodide Treatment (RAIT), Differentiated Thyroid Cancer (DTC), radiotheragnostics, Post Total Thyroidectomy (PTT), Treatment of Known Disease (TKD), thyroglobulin.

[1]
Fahey FH, Grant FD, Thrall JH. Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys 2017; 4(1): 15.
[http://dx.doi.org/10.1186/s40658-017-0182-7] [PMID: 28451906]
[2]
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc 1946; 132(14): 838-47.
[http://dx.doi.org/10.1001/jama.1946.02870490016004] [PMID: 20274882]
[3]
Brucer M. From Surgery without a Knife to the Atomic CocktailVignettes in Nuclear Medicine I. St. Louis, Missouri: Mallinckrodt Chemical Works 1969; pp. 1-11.
[5]
Min JJ, Chung JK, Lee Y, et al. Relationship between expression of the sodium/iodide symporter and (131)I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001; 28(5): 639-45.
[http://dx.doi.org/10.1007/s002590100509] [PMID: 24633540]
[6]
Rawson RW, Marinelli LD, et al. The effect of total thyroidectomy on the function of metastatic thyroid cancer. J Clin Endocrinol Metab 1948; 8(10): 826-41.
[http://dx.doi.org/10.1210/jcem-8-10-826] [PMID: 18890104]
[7]
Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87: 171-82.
[PMID: 13867399]
[8]
Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984; 25(12): 1287-93.
[PMID: 6502251]
[9]
Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, et al. Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer. J Nucl Med 2016.
[PMID: 27738010]
[10]
Flux GD, Verburg FA, Chiesa C, et al. Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. J Nucl Med 2017; 58(5): 862.
[http://dx.doi.org/10.2967/jnumed.116.186643] [PMID: 28183989]
[11]
Jentzen W, Nahum AE, Bockisch A, Binse I, Tulchinsky M. Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History. J Nucl Med 2017; 58(9): 1530.
[http://dx.doi.org/10.2967/jnumed.117.192872] [PMID: 28385792]
[12]
Tulchinsky M, Gross LJ. Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. J Nucl Med 2017; 58(5): 863.
[http://dx.doi.org/10.2967/jnumed.117.190199] [PMID: 28232615]
[13]
Van Nostrand D. Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer. J Nucl Med 2017; 58(5): 697-9.
[http://dx.doi.org/10.2967/jnumed.116.188862] [PMID: 28209908]
[14]
Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309(16): 937-41.
[http://dx.doi.org/10.1056/NEJM198310203091601] [PMID: 6621620]
[15]
Maxon HR III, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33(6): 1132-6.
[PMID: 1597728]
[16]
Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45(8): 1366-72.
[PMID: 15299063]
[17]
Jentzen W, Hoppenbrouwers J, van Leeuwen P, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med 2014; 55(11): 1759-65.
[http://dx.doi.org/10.2967/jnumed.114.144089] [PMID: 25332440]
[18]
Jentzen W, Bockisch A, Ruhlmann M. Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I. J Nucl Med 2015; 56(6): 832-8.
[http://dx.doi.org/10.2967/jnumed.114.153031] [PMID: 25858042]
[19]
Jentzen W, Verschure F, van Zon A, et al. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer. J Nucl Med 2016; 57(10): 1499-504.
[http://dx.doi.org/10.2967/jnumed.115.170571] [PMID: 27199362]
[20]
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97(5): 418-28.
[http://dx.doi.org/10.1016/0002-9343(94)90321-2] [PMID: 7977430]
[21]
Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91(3): 926-32.
[http://dx.doi.org/10.1210/jc.2005-1651] [PMID: 16384850]
[22]
Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77(12): 2574-80.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2574:AID-CNCR22>3.0.CO;2-O] [PMID: 8640708]
[23]
Brown SR, Hall A, Buckley HL, et al. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer 2019; 19(1): 582.
[http://dx.doi.org/10.1186/s12885-019-5541-4] [PMID: 31200667]
[24]
Wadsley J, Gregory R, Flux G, et al. SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective. Br J Radiol 2017; 90(1073)20160637
[http://dx.doi.org/10.1259/bjr.20160637] [PMID: 28291381]
[25]
Van Nostrand D. Radioiodine Theranostics: Increasing Dialogue and Collaboration. J Nucl Med 2017; 58(10): 19N-20N.
[PMID: 28970353]
[26]
Tuttle RM, Ahuja S, Avram AM, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 2019; 29(4): 461-70.
[http://dx.doi.org/10.1089/thy.2018.0597] [PMID: 30900516]
[27]
Rosenthal MS, Angelos P, Bible K, Fassler CA, Finder S, Wissner Greene L, et al. Informed consent for low-risk thyroid cancer. Int J Endocr Oncol 2016; 3(2): 131-42.
[http://dx.doi.org/10.2217/ije-2015-0010]
[28]
Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med 2012; 53(5): 754-64.
[PMID: 22550280]
[29]
Dizdarevic S, Tulchinsky M, McCready VR, et al. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. World J Nucl Med 2019; 18(2): 123-6.
[http://dx.doi.org/10.4103/wjnm.WJNM_117_18] [PMID: 31040741]
[30]
Avram AM, Esfandiari NH, Wong KK. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. J Clin Endocrinol Metab 2015; 100(5): 1895-902.
[http://dx.doi.org/10.1210/jc.2014-4043] [PMID: 25734251]
[31]
Avram AM, Rosculet N, Esfandiari NH, et al. Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics. Clin Nucl Med 2019; 44(1): 11-20.
[http://dx.doi.org/10.1097/RLU.0000000000002321] [PMID: 30371575]
[32]
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1): 1-133.
[http://dx.doi.org/10.1089/thy.2015.0020] [PMID: 26462967]
[33]
Luster M, Aktolun C, Amendoeira I, Barczynski M, Bible KC, Duntas LH, et al. European perspective on the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer Proceedings of an interactive international symposium Thyroid
[34]
Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 2012; 53(10): 1633-51.
[http://dx.doi.org/10.2967/jnumed.112.105148] [PMID: 22787108]
[35]
Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327(7429): 1459-61.
[http://dx.doi.org/10.1136/bmj.327.7429.1459] [PMID: 14684649]
[36]
Tulchinsky M, Baum RP, Bennet KG, et al. Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms. J Clin Oncol 2018; 36(18): 1887-8.
[http://dx.doi.org/10.1200/JCO.2018.78.5972] [PMID: 29723091]
[37]
van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE, et al. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/ Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid CancerThyroid. 2018; 28: pp. (8)976-81. In:
[38]
Onitilo AA, Engel JM, Lundgren CI, Hall P, Thalib L, Doi SA. Simplifying the TNM system for clinical use in differentiated thyroid cancer. J Clin Oncol 2009; 27(11): 1872-8.
[http://dx.doi.org/10.1200/JCO.2008.20.2382] [PMID: 19273697]
[39]
Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102(6): 1088-95.
[PMID: 3686348]
[40]
Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104(6): 947-53.
[http://dx.doi.org/10.1016/S0039-6060(98)70034-0] [PMID: 3194846]
[41]
Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 1992; 112(6): 1154-9.
[PMID: 1455318]
[42]
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114(6): 1050-7.
[PMID: 8256208]
[43]
Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer 2007; 14(1): 29-42.
[http://dx.doi.org/10.1677/erc.1.01284] [PMID: 17395973]
[44]
Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43(2): 401-21.
[http://dx.doi.org/10.1016/j.ecl.2014.02.010] [PMID: 24891169]
[45]
Pitoia F, Jerkovich F, Urciuoli C, et al. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. Thyroid 2015; 25(11): 1235-42.
[http://dx.doi.org/10.1089/thy.2015.0121] [PMID: 26132983]
[46]
Domínguez JM, Martínez MT, Massardo JM, et al. Risk of recurrence in differentiated thyroid cancer Rev Med Chil 2018; 146(3): 282-9.
[PMID: 29999097]
[47]
Bates MF, Lamas MR, Randle RW, et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 2018; 163(1): 118-23.
[http://dx.doi.org/10.1016/j.surg.2017.05.028] [PMID: 29128176]
[48]
Albano D, Bertagna F, Panarotto MB, Giubbini R. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. Pediatr Blood Cancer 2017; 64(11)
[http://dx.doi.org/10.1002/pbc.26595] [PMID: 28436606]
[49]
Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma-a systematic review. Cancer Treat Rev 2015; 41(10): 925-34.
[http://dx.doi.org/10.1016/j.ctrv.2015.09.001] [PMID: 26421813]
[50]
Fard-Esfahani A, Emami-Ardekani A, Fallahi B, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 2014; 35(8): 808-17.
[http://dx.doi.org/10.1097/MNM.0000000000000132] [PMID: 24751702]
[51]
Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46(2): 261-6.
[PMID: 15695785]
[52]
Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial. J Nucl Med 2010; 51(4): 618-23.
[http://dx.doi.org/10.2967/jnumed.109.071449] [PMID: 20237029]
[53]
Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008; 49(4): 546-9.
[http://dx.doi.org/10.2967/jnumed.107.049411] [PMID: 18344428]
[54]
Atienza G, López-Cedrún JL. Management of obstructive salivary disorders by sialendoscopy: a systematic review. Br J Oral Maxillofac Surg 2015; 53(6): 507-19.
[http://dx.doi.org/10.1016/j.bjoms.2015.02.024] [PMID: 25823614]
[55]
Bhayani MK, Acharya V, Kongkiatkamon S, et al. Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia. Thyroid 2015; 25(7): 834-8.
[http://dx.doi.org/10.1089/thy.2014.0572] [PMID: 25860842]
[56]
Kim YM, Choi JS, Hong SB, Hyun IY, Lim JY. Salivary gland function after sialendoscopy for treatment of chronic radioiodine-induced sialadenitis. Head Neck 2016; 38(1): 51-8.
[http://dx.doi.org/10.1002/hed.23844] [PMID: 24995941]
[57]
Wu CB, Xi H, Zhou Q, Zhang LM. Sialendoscopy-assisted treatment for radioiodine-induced sialadenitis. J Oral Maxillofac Surg 2015; 73(3): 475-81.
[http://dx.doi.org/10.1016/j.joms.2014.09.025] [PMID: 25544300]
[58]
Dingle IF, Mishoe AE, Nguyen SA, Overton LJ, Gillespie MB. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer. Otolaryngol Head Neck Surg 2013; 148(5): 746-52.
[http://dx.doi.org/10.1177/0194599813479777] [PMID: 23462656]
[59]
Angelidis G, Tsougos I, Valotassiou V, Georgoulias P. Low-dose radiation cancer risk hypothesis may lead to ‘radiophobia’-driven imaging avoidance? J Nucl Cardiol 2018.
[http://dx.doi.org/10.1007/s12350-018-1354-0]
[60]
Yu CY, Saeed O, Goldberg AS, et al. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. Thyroid 2018; 28(12): 1662-73.
[http://dx.doi.org/10.1089/thy.2018.0244] [PMID: 30370820]
[61]
Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. J Clin Oncol 2017; 7(50): 232.
[PMID: 29252123]
[62]
Vaiano A, Claudio Traino A, Boni G, et al. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl Med Commun 2007; 28(3): 215-23.
[http://dx.doi.org/10.1097/MNM.0b013e328014a0f6] [PMID: 17264781]
[63]
Hung GU, Ho M, Kao CH. Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone. Clin Nucl Med 2009; 34(5): 316-7.
[http://dx.doi.org/10.1097/RLU.0b013e31819e5108] [PMID: 19387216]
[64]
Freudenberg LS, Jentzen W, Petrich T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging 2010; 37(12): 2267-76.
[http://dx.doi.org/10.1007/s00259-010-1565-3] [PMID: 20661558]
[65]
Zanotti-Fregonara P, Hindié E. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37(12): 2264-6.
[http://dx.doi.org/10.1007/s00259-010-1608-9] [PMID: 20821206]
[66]
Van Nostrand D, Khorjekar GR, O’Neil J, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J Nucl Med 2012; 53(3): 359-62.
[http://dx.doi.org/10.2967/jnumed.111.096016] [PMID: 22315442]
[67]
Smith CD, Grondin R, LeMaster W, Martin B, Gold BT, Ain KB. Reversible cognitive, motor, and driving impairments in severe hypothyroidism. Thyroid 2015; 25(1): 28-36.
[http://dx.doi.org/10.1089/thy.2014.0371] [PMID: 25381990]
[68]
Giovanella L, Castellana M, Trimboli P. Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer. Clin Chem Lab Med 2019; 58(1): 130-7.
[http://dx.doi.org/10.1515/cclm-2019-0654] [PMID: 31444962]
[69]
Mourão GF, Rosario PW, Calsolari MR. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation. Endocr Relat Cancer 2016; 23(1): 47-52.
[http://dx.doi.org/10.1530/ERC-15-0458] [PMID: 26503963]
[70]
Avram AM, Fig LM, Frey KA, Gross MD, Wong KK. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab 2013; 98(3): 1163-71.
[http://dx.doi.org/10.1210/jc.2012-3630] [PMID: 23430789]
[71]
Verkooijen RB, Rietbergen D, Smit JW, Romijn JA, Stokkel MP. A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up. Eur J Endocrinol 2007; 156(1): 41-7.
[http://dx.doi.org/10.1530/eje.1.02322] [PMID: 17218724]
[72]
Clark P, Franklyn J. Can we interpret serum thyroglobulin results? Ann Clin Biochem 2012; 49(Pt 4): 313-22.
[http://dx.doi.org/10.1258/acb.2011.011248] [PMID: 22589360]
[73]
Thomas N, Gent ML, Tulchinsky M. Thyroglobulin Levels Relative to the 24 Hour Radioiodine Uptake in the Thyroid Bed May Help Identify Residual Disease Post-Thyroidectomy in Differentiated Thyroid Carcinoma Washington. DC: Endocrine Society 2015. Available at: https://endo.confex.com/endo/2015endo/webprogram/Paper21538.html
[74]
Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37(9): 1468-72.
[PMID: 8790195]
[75]
Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005; 115(2): 237-43.
[http://dx.doi.org/10.1097/01.mlg.0000154725.00787.00] [PMID: 15689742]
[76]
Lee JW, Min HS, Lee SM, Kwon HW, Chung JK. Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases. Nucl Med Mol Imaging 2015; 49(2): 127-34.
[http://dx.doi.org/10.1007/s13139-015-0324-6] [PMID: 26085858]
[77]
Wiebel JL, Esfandiari NH, Papaleontiou M, Worden FP, Haymart MR. Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer. Thyroid 2015; 25(9): 1026-32.
[http://dx.doi.org/10.1089/thy.2015.0062] [PMID: 26133765]
[78]
Caetano R, Bastos CR, de Oliveira IA, et al. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis. Head Neck 2016; 38(2): 316-27.
[http://dx.doi.org/10.1002/hed.23881] [PMID: 25251544]
[79]
Haslerud T, Brauckhoff K, Reisæter L, et al. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. Acta Radiol 2016; 57(10): 1193-200.
[http://dx.doi.org/10.1177/0284185115594645] [PMID: 26163534]
[80]
Cherk MH, Kalff V, Yap KS, Bailey M, Topliss D, Kelly MJ. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 69(6): 957-62.
[http://dx.doi.org/10.1111/j.1365-2265.2008.03276.x] [PMID: 18419785]
[81]
Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368(7): 623-32.
[http://dx.doi.org/10.1056/NEJMoa1209288] [PMID: 23406027]
[82]
Banerjee M, Wiebel JL, Guo C, Gay B, Haymart MR. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. BMJ 2016; 354: i3839.
[http://dx.doi.org/10.1136/bmj.i3839] [PMID: 27443325]
[83]
Kaul S, Tulchinsky M, Campbell DB, Crist HS, Manni A. Isolated cardiac metastasis from papillary thyroid cancer: prolonged survival with late diagnosis related to inadequate positron emission tomography preparation. Thyroid 2012; 22(4): 443-4.
[http://dx.doi.org/10.1089/thy.2011.0295] [PMID: 22376168]
[84]
Avram AM, Dewaraja YK. Thyroid Cancer Radiotheragnostics: the case for activity adjusted 131I therapy. Clin Transl Imaging 2018; 6(5): 335-46.
[http://dx.doi.org/10.1007/s40336-018-0291-x] [PMID: 30911535]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 31
Year: 2020
Published on: 16 September, 2020
Page: [3812 - 3827]
Pages: 16
DOI: 10.2174/1381612826666200605121054

Article Metrics

PDF: 28
HTML: 4